Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CGEM Cullinan Oncology Inc
- Stocks
- Healthcare
- NASDAQ: CGEM
Price (delayed)
$7.76
Market cap
$457.95M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.66
Enterprise value
$383.14M
Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build
Highlights
The debt has declined by 42% year-on-year and by 14% since the previous quarter
Cullinan Oncology's equity has increased by 30% YoY but it has decreased by 7% from the previous quarter
The EPS is down by 4.7% year-on-year but it is up by 4.3% since the previous quarter
CGEM's quick ratio is down by 44% YoY and by 15% from the previous quarter
CGEM's net income is down by 35% YoY and by 7% from the previous quarter
Key stats
What are the main financial stats of CGEM
Market
Valuations
Earnings
Shares outstanding
59.01M
Market cap
$457.95M
Enterprise value
$383.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.82
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$208.93M
Net income
-$178.74M
EBIT
-$178.62M
EBITDA
-$178.31M
Free cash flow
-$150.21M
Per share
Balance sheet
Liquidity
EPS
-$2.66
EPS diluted
-$2.66
Free cash flow per share
-$2.55
Book value per share
$9.43
Revenue per share
$0
TBVPS
$9.84
Total assets
$579.68M
Total liabilities
$27.84M
Debt
$1.84M
Equity
$551.84M
Working capital
$290.42M
Debt to equity
0
Current ratio
11.62
Quick ratio
11.11
Net debt/EBITDA
0.42
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-28.4%
Return on equity
-29.7%
Return on invested capital
-34.6%
Return on capital employed
-32.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CGEM stock price
How has the Cullinan Oncology stock price performed over time
Intraday
1.57%
1 week
-2.02%
1 month
-11.31%
1 year
-52.42%
YTD
-36.29%
QTD
3.05%
Financial performance
How have Cullinan Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$208.93M
Net income
-$178.74M
Gross margin
N/A
Net margin
N/A
CGEM's net income is down by 35% YoY and by 7% from the previous quarter
The operating income has contracted by 22% YoY and by 6% from the previous quarter
Price vs fundamentals
How does CGEM's price correlate with its fundamentals
Growth
What is Cullinan Oncology's growth rate over time
Valuation
What is Cullinan Oncology stock price valuation
P/E
N/A
P/B
0.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 4.7% year-on-year but it is up by 4.3% since the previous quarter
The price to book (P/B) is 41% lower than the 5-year quarterly average of 1.4 and 37% lower than the last 4 quarters average of 1.3
Cullinan Oncology's equity has increased by 30% YoY but it has decreased by 7% from the previous quarter
Efficiency
How efficient is Cullinan Oncology business performance
CGEM's return on invested capital is up by 12% year-on-year
The company's return on assets fell by 3.6% YoY
Cullinan Oncology's return on equity has decreased by 2.8% YoY
Dividends
What is CGEM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CGEM.
Financial health
How did Cullinan Oncology financials performed over time
CGEM's quick ratio is down by 44% YoY and by 15% from the previous quarter
The current ratio has declined by 43% year-on-year and by 14% since the previous quarter
The debt is 100% smaller than the equity
CGEM's debt to equity has dropped by 100% year-on-year
The debt has declined by 42% year-on-year and by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.